

Ilaria Vicenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4457548/publications.pdf>

Version: 2024-02-01

65
papers

930
citations

516215

16
h-index

525886

27
g-index

68
all docs

68
docs citations

68
times ranked

1836
citing authors

#	ARTICLE	IF	CITATIONS
1	The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. <i>Infection</i> , 2022, 50, 541-543.	2.3	10
2	External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. <i>Scientific Reports</i> , 2022, 12, 3291.	1.6	4
3	Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	5
4	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. <i>Scientific Reports</i> , 2022, 12, 5736.	1.6	6
5	Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. <i>Vaccines</i> , 2022, 10, 580.	2.1	2
6	SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility. <i>Cells</i> , 2022, 11, 1431.	1.8	11
7	Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. <i>Viruses</i> , 2022, 14, 1374.	1.5	15
8	Impact of pre-existing drug resistance on virological efficacy of single-tablet regimens in people living with HIV. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106636.	1.1	1
9	<i>In vitro</i> cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 130-134.	1.3	12
10	Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells. <i>Journal of General Virology</i> , 2021, 102, .	1.3	1
11	Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2670.	1.8	4
12	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 325-337.	2.4	84
13	Surveillance for Severe Acute Respiratory Infections among Hospitalized Subjects from 2015/2016 to 2019/2020 Seasons in Tuscany, Italy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3875.	1.2	0
14	Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab312.	0.4	4
15	Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. <i>International Journal of Infectious Diseases</i> , 2021, 108, 176-178.	1.5	26
16	Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2021, 13, 1347.	1.5	12
17	BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. <i>Life</i> , 2021, 11, 896.	1.1	2
18	<i>In vitro</i> susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3310-3312.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021. <i>Virology Journal</i> , 2021, 18, 168.	1.4	36
20	Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals. <i>Journal of Infection</i> , 2021, , .	1.7	3
21	Bithiazole Inhibitors of Phosphatidylinositol 4-kinase (PI4KIII ²) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses. <i>ChemMedChem</i> , 2021, 16, 3548-3552.	1.6	13
22	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113683.	2.6	9
23	Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. <i>International Journal of Infectious Diseases</i> , 2021, 112, 40-44.	1.5	31
24	In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study. <i>Biomolecules</i> , 2021, 11, 1858.	1.8	11
25	Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 163-169.	0.9	12
26	Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. <i>Molecules</i> , 2020, 25, 5695.	1.7	64
27	Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012. <i>Proceedings (mdpi)</i> , 2020, 50, .	0.2	0
28	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. <i>Viruses</i> , 2020, 12, 798.	1.5	46
29	Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9876-9887.	2.9	7
30	Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. <i>SLAS Discovery</i> , 2020, 25, 506-514.	1.4	13
31	Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. <i>Viruses</i> , 2020, 12, 641.	1.5	13
32	Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. <i>Antiviral Research</i> , 2020, 175, 104708.	1.9	30
33	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 956-962.	1.3	19
34	Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA. <i>Antiviral Therapy</i> , 2020, 25, 61-71.	0.6	11
35	Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. <i>Infezioni in Medicina</i> , 2020, 28, 576-586.	0.7	0
36	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1443-1446.	2.8	8

#	ARTICLE	IF	CITATIONS
37	No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.. Antiviral Research, 2019, 172, 104635.	1.9	8
38	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes, 2019, 55, 290-297.	0.7	0
39	Comparable <i>In Vitro</i> Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	15
40	The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine <i>in vitro</i> . Journal of Antimicrobial Chemotherapy, 2019, 74, 607-613.	1.3	9
41	Prevalence and determinants of resistance mutations in HIV-1 infected patients exposed to integrase inhibitors in a large Italian cohort. HIV Medicine, 2019, 20, 137-146.	1.0	15
42	Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A. Journal of Clinical Virology, 2019, 111, 12-18.	1.6	6
43	Agreement between an <i>in-house</i> replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors. Journal of Clinical Laboratory Analysis, 2018, 32, .	0.9	22
44	Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood. Clinical Chemistry and Laboratory Medicine, 2018, 56, e75-e77.	1.4	14
45	Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds <i>in vitro</i> . Virus Research, 2018, 244, 64-70.	1.1	47
46	Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia. New Microbiologica, 2018, 41, 302-305.	0.1	3
47	The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir <i>in vitro</i> . Aids, 2017, 31, 2307-2309.	1.0	12
48	Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs?. Frontiers in Immunology, 2017, 8, 1966.	2.2	3
49	Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. Journal of Clinical Virology, 2016, 83, 48-53.	1.6	5
50	Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing. Future Virology, 2016, 11, 731-744.	0.9	0
51	Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. Journal of Clinical Virology, 2016, 76, 20-23.	1.6	4
52	Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania. AIDS Research and Human Retroviruses, 2015, 31, 448-451.	0.5	2
53	Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR. Journal of Virological Methods, 2015, 224, 102-104.	1.0	2
54	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infectious Diseases, 2015, 2, ofv043.	0.4	30

#	ARTICLE	IF	CITATIONS
55	Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism. <i>BMC Infectious Diseases</i> , 2013, 13, 508.	1.3	1
56	Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 299-303.	0.5	2
57	Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 984-987.	1.3	54
58	Changing patterns in HIV-1 CR1 clade prevalence and diversity in Italy over three decades*. <i>HIV Medicine</i> , 2010, 11, 593-602.	1.0	54
59	Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy. <i>Clinical Microbiology and Infection</i> , 2010, 16, 848-851.	2.8	2
60	Impact of Remote versus Local Sampling on Sensitivity of Genotypic Antiretroviral Resistance Testing. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2321-2322.	1.8	0
61	Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 616-624.	1.3	34
62	Three-Class-Resistant Human Immunodeficiency Virus Type 1 Variant in a Drug-Naive Heterosexual Couple. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3856-3859.	1.8	1
63	Use of Peripheral Blood DNA for Genotype Antiretroviral Resistance Testing in Drug-Naive HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2007, 44, 1657-1661.	2.9	26
64	Natural Variability in the HR-1 and HR-2 Domains of HIV Type 1 gp41 from Different Clades Circulating in Italy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 558-563.	0.5	9
65	Evidence of Differential Selection of HIV-1 Variants Carrying Drug-Resistant Mutations in Seroconverters. <i>Antiviral Therapy</i> , 2006, 11, 329-334.	0.6	16